Source - LSE Non-Regulatory
RNS Number : 0185S
ValiRx PLC
11 November 2021

11 November 2021


ValiRx PLC ("ValiRx" or the "Company")


Live Shareholder Q&A and Investor presentations


Live Q&A: London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, invites shareholders to join the CEO, Chairman and Corporate Development Manager in a Zoom webinar on 25 November 2021 at 2pm (UK). Registration prior to the event is recommended to ensure all notifications about the webinar are received by participants. Registration details will be available on the ValiRx website closer to the event. The format will comprise a short presentation by the Company on latest developments, followed by an invitation to shareholders to activate their cameras and speak directly with the ValiRx team. A recording of the event will be available to view from the ValiRx website shortly after the event concludes.

LSE Investor Presentation: CEO, Dr Suzy Dilly will also be presenting at this event on the evening of 7 December (6pm - 8pm (UK)). Prior registration is required directly with LSE, which can be accessed at  The format will be a short presentation and audience Q&A.

Corporate Update: The Company is also pleased to inform shareholders that the entry on for the recently completed VAL201 clinical trial has now been finalised with the addition of a summary of raw data results.

Dr Suzy Dilly, CEO of ValiRx commented: "I am looking forward to joining our shareholders in further live discussions as we continue building our events schedule to achieve transparent shareholder communications. Further conversations about our recent scientific and commercial advances, as well as conversations around our emerging strategy in Women's Health are important as we wish to ensure that shareholders understand how we are intending to continue to build long term value into the Company."


*** ENDS ***


For more information, please contact:


ValiRx plc


Dr Suzanne Dilly, CEO


Tel: +44 (0) 2476 796496

Cenkos Securities Limited (Broker)


Russell Kerr/Michael Johnson (Sales)


Callum Davidson/Giles Balleny (Corporate Finance)

Tel: +44 (0) 20 7397 8900


Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.




This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.